Weight loss
that works with
your biology.

Complete a short health questionnaire, get matched with a US-licensed provider who reviews your information and (where clinically appropriate) writes a prescription, and receive medication shipped directly from a US-licensed pharmacy. The entire process is online — no office visits required.

Pallas offers both compounded GLP-1s and FDA-approved brand-name GLP-1s. Compounded semaglutide and tirzepatide are prepared on a per-patient basis by US-licensed compounding pharmacies when a licensed provider determines they are clinically appropriate. 503A pharmacies are licensed and inspected by state boards of pharmacy, and 503B outsourcing facilities are registered with and inspected by the FDA under current Good Manufacturing Practice (cGMP) standards. While these facilities are subject to regulatory oversight, the compounded medications themselves are not FDA-approved products, are not generic versions of brand-name drugs (such as Ozempic^®, Wegovy^®, Mounjaro^®, or Zepbound^®), and have not been evaluated by the FDA for safety, efficacy, or quality. Pallas also dispenses FDA-approved brand-name Wegovy^®, Ozempic^®, Zepbound^®, and Mounjaro^® through US-licensed pharmacies on a cash-pay basis when clinically appropriate.

Outcomes vary by individual and depend on starting weight, adherence, dose, lifestyle, and other clinical factors; outcomes are not guaranteed. The FDA-approved products Wegovy^® (Novo Nordisk) and Zepbound^® (Eli Lilly) have published Phase 3 trial data, but those results were observed with the FDA-approved products studied in the trials and have not been clinically established for compounded medications.

No insurance required. Pallas operates outside of insurance for simpler, more affordable, and more accessible care — all plans are cash-pay and not billed to insurance. Compounded semaglutide injection is $269/month, oral semaglutide is $299/month, and tirzepatide injection is $359/month. FDA-approved brand-name GLP-1s are also available — Wegovy^® and Ozempic^® (semaglutide) and Zepbound^® and Mounjaro^® (tirzepatide) — from $1,069/month. Quarterly bundles are available on compounded plans, and everything is included — provider visits, medication, and free shipping.

Reported side effects of GLP-1 medications include nausea, constipation, diarrhea, vomiting, abdominal pain, and headache. These typically subside within the first few weeks. Serious side effects can include pancreatitis, gallbladder disease, kidney injury, and allergic reactions. See our full safety information for the FDA boxed warning regarding thyroid C-cell tumors. Your provider will guide you through dose titration and monitor for side effects.

Yes. You can cancel or pause your subscription at any time through your account or by emailing us — no penalties, no cancellation fees.

Compounded plans: semaglutide injection $269/month ($657/quarter), oral semaglutide $299/month ($777/quarter), tirzepatide injection $359/month ($927/quarter). FDA-approved brand-name GLP-1s, cash-pay: Zepbound^® $1,069/month, Mounjaro^® $1,349/month, Ozempic^® $1,299/month, and Wegovy^® $1,349/month. Each plan includes the medication, ongoing licensed-provider support, dose adjustments, and free shipping. No hidden fees.

After your provider writes the prescription, the pharmacy typically ships within 2–3 business days. Most members receive their first shipment within a week of approval.

Pallas care is delivered by Lion MD, a nationwide team of US-licensed medical professionals, in partnership with CareValidate, our clinical-operations platform. Our medical leadership — Dr. Ana Lisa Carr, MD (NPI: 1689841744) and Dr. Kelly Tenbrink, MD (NPI: 1346482684) — and their licensure are posted publicly on our clinical disclosures page at pallashealth.co/clinical, where each NPI links to the federal NPPES NPI Registry for independent verification. Every prescribing provider holds an active license in the state or jurisdiction where the patient is located, and each patient also receives their assigned provider's name and license information before a prescription is issued.

Pallas works with a network of US-licensed compounding pharmacies that prepare medications on a per-patient basis when a Pallas provider determines they are clinically appropriate. Our partner pharmacies include Belmar Pharmacy (800-525-9473, belmarpharmasolutions.com), Strive Pharmacy (855-405-5993, strivepharmacy.com), Epiq Scripts (833-654-3553, epiqscripts.com), Casa Pharma Rx (877-937-6868, casapharmarx.com), The Pharmacy Hub (888-958-1382, thepharmacyhub.com), and Foothills Pharmacy (480-496-4444, foothillspharmacy.com). 503A pharmacies are licensed and inspected by state boards of pharmacy, and 503B outsourcing facilities are registered with and inspected by the FDA under current Good Manufacturing Practice (cGMP) standards. Compounded medications are not FDA-approved, are not generic versions of brand-name drugs, and have not been evaluated by the FDA for safety, efficacy, or quality.

Pallas is available in all 50 states and Washington, D.C. Every prescribing provider holds an active license in the state or jurisdiction where the patient is located, so care is coordinated to your home jurisdiction at the time of consultation.